Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
List view / Grid view
Solid tumour cancer
Blend presents preclinical data for BTP-114 that demonstrates superiority to cisplatin in tumour growth inhibition
22 April 2015 | By Victoria White
Blend Therapeutics has presented preclinical data on it's lead product candidate, BTP-114, a novel personalised cisplatin prodrug, at AACR 2015...